ANSWER: C

Rationale:

The critical pharmacokinetic distinction between ETI and lumacaftor-ivacaftor in the context of tacrolimus co-administration is that neither elexacaftor nor tezacaftor induces cytochrome P450 isoform CYP3A4 (CYP3A4), the primary enzyme responsible for tacrolimus hepatic and intestinal metabolism. Lumacaftor is a potent CYP3A4 inducer that would markedly accelerate tacrolimus metabolism, reducing trough concentrations and risking allograft rejection — an interaction that makes lumacaftor-ivacaftor dangerous in transplant patients on calcineurin inhibitors. Because ETI's corrector components lack this induction activity, ETI does not carry this dangerous tacrolimus-lowering interaction, and the regimen can be initiated in this post-transplant patient. However, tacrolimus is a narrow therapeutic index immunosuppressant that is highly sensitive to even modest pharmacokinetic perturbations; the full interaction profile of the ETI combination with tacrolimus is not exhaustively characterized for all possible transporter-level effects. Ivacaftor, while not a potent CYP3A4 inducer, may have modest effects at the CYP3A4 or P-glycoprotein level. Therefore, increased frequency tacrolimus trough monitoring — ideally weekly for the first 4 to 6 weeks after ETI initiation — is appropriate to confirm that immunosuppressive concentrations remain stable during the transition, with dose adjustments made as needed.

• Option A: Option A is incorrect because elexacaftor is a CFTR corrector that acts on misfolded CFTR protein in the endoplasmic reticulum and has no pharmacodynamic interaction with calcineurin phosphatase or tacrolimus's mechanism of T-cell immunosuppression; the described calcineurin inhibitor antagonism is pharmacologically fabricated.
• Option B: Option B is incorrect because tezacaftor is not a clinically significant P-glycoprotein inhibitor and does not produce the four- to five-fold increase in tacrolimus bioavailability described; no such interaction is established in the ETI prescribing labeling.
• Option D: Option D is incorrect because tacrolimus is substantially metabolized by CYP3A4 — it is not eliminated exclusively by renal tubular secretion; renal transplant restores glomerular filtration but does not alter tacrolimus's hepatic CYP3A4 metabolism, and standard quarterly monitoring is insufficient when initiating a new drug combination in a transplant patient on a narrow therapeutic index agent.
• Option E: Option E is incorrect because tacrolimus is not a clinically significant CYP3A4 inhibitor at standard therapeutic blood concentrations; the every-other-day ETI adjustment is the labeled protocol for strong CYP3A4 inhibitors such as azole antifungals, and tacrolimus co-administration does not trigger this adjustment.

ANSWER: A

Rationale:

The discordance between dramatic sweat chloride normalization and modest FEV1 improvement is a recognized and clinically predictable pattern in ETI-treated patients with pre-existing structural lung disease. Sweat chloride concentration reflects CFTR channel activity in sweat duct epithelium — tissue that has no accumulated structural damage from CF lung disease, no fibrosis, and no chronic infection. When ETI restores CFTR function pharmacologically, sweat duct epithelium responds faithfully and rapidly, and the sweat chloride reduction to 31 mmol/L confirms that ETI is producing genuine and robust CFTR functional restoration at the molecular level. FEV1, by contrast, is a measure of airflow through pulmonary airways that have sustained decades of cumulative structural injury from CFTR dysfunction: bilateral bronchiectatic airway dilation with destroyed wall elasticity and muscular architecture, fibrotic remodeling, mucus plugging from impaired mucociliary clearance, and chronic endobronchial bacterial colonization producing ongoing inflammation. These structural changes do not reverse with CFTR functional restoration — as demonstrated by CT imaging studies in ETI-treated adults — and they impose a structural ceiling on achievable FEV1 improvement that is independent of the degree of pharmacological CFTR rescue. The modest 5-percentage-point FEV1 gain reflects this structural disease burden, not a failure of ETI to work. The patient's clinical benefit extends substantially beyond the spirometric change: his risk of pulmonary exacerbations is reduced, his nutritional status and quality of life will improve, and the trajectory of further decline has been favorably altered.

• Option B: Option B is incorrect because tacrolimus does not inhibit CFTR-mediated chloride secretion in sweat duct epithelium at therapeutic trough concentrations; no such pharmacodynamic interaction between calcineurin inhibitors and CFTR channel activity is established, and tacrolimus is not a recognized confounder of sweat chloride testing.
• Option C: Option C is incorrect because a sweat chloride of 31 mmol/L does represent substantial normalization — the threshold for normal is below 30 mmol/L — and a 5-percentage-point FEV1 improvement in a patient with bilateral moderate bronchiectasis and a baseline of 44% is consistent with established ETI real-world data in patients with severe structural disease; ETI underdosing is not the clinical interpretation.
• Option D: Option D is incorrect because progressive year-over-year FEV1 improvement of 5 percentage points annually over 3 to 5 years is not the established pattern in ETI-treated adults with severe structural disease; established bronchiectasis does not undergo ongoing reversal with sustained ETI therapy, and projecting near-complete bronchiectasis reversal at 5 years misrepresents the current evidence.
• Option E: Option E is incorrect because sweat chloride normalization is a direct validated biomarker of CFTR channel function in sweat duct epithelium, not a marker of anti-inflammatory effects; the mechanism is CFTR-mediated chloride secretion restoration, and the measurement is well-established as a pharmacodynamic readout of CFTR modulator activity.

ANSWER: D

Rationale:

Rifampin creates two simultaneous and independently dangerous pharmacokinetic problems in this patient that together argue strongly for a rifampin-free MAC regimen. First, rifampin is a potent inducer of cytochrome P450 isoform CYP3A4 (CYP3A4) — the primary enzyme responsible for ivacaftor hepatic metabolism. The ETI and ivacaftor prescribing labels explicitly classify rifampin and other potent CYP3A4 inducers as agents to be avoided with any ivacaftor-containing regimen, because rifampin-driven CYP3A4 induction markedly reduces ivacaftor plasma concentrations to potentially sub-therapeutic levels, compromising CFTR potentiation and eliminating the clinical benefits this patient has worked to achieve over 8 months. Unlike the CYP3A4 inhibitor interaction — where the labeled every-other-day adjustment compensates for reduced ivacaftor clearance — no validated dose-escalation protocol exists to reliably compensate for rifampin's potent induction of ivacaftor clearance; avoidance of the combination is the correct approach. Second, tacrolimus is a narrow therapeutic index CYP3A4 substrate; rifampin's CYP3A4 induction substantially accelerates tacrolimus metabolism, reducing tacrolimus trough concentrations and creating a serious risk of sub-therapeutic immunosuppression and acute allograft rejection in a patient who is only 3 years post-kidney transplant. Managing this interaction requires aggressive tacrolimus dose escalation and intensive monitoring — a complex and high-risk undertaking. The combination of both interactions simultaneously makes rifampin-containing therapy particularly dangerous in this patient. A rifampin-free MAC regimen — azithromycin, ethambutol, and amikacin — is the standard alternative and avoids both CYP3A4 induction interactions.

• Option A: Option A is incorrect because rifampin is a CYP3A4 inducer, not an inhibitor; it reduces rather than raises ivacaftor and tacrolimus concentrations, and the every-other-day ETI adjustment applies to CYP3A4 inhibitors, not inducers.
• Option B: Option B is incorrect because ivacaftor is a CYP3A4 substrate — rifampin's CYP3A4 induction markedly reduces ivacaftor concentrations; the claim that rifampin has no clinically significant interaction with ETI because the correctors are not CYP3A4 substrates ignores ivacaftor, which is the component critically affected.
• Option C: Option C is incorrect because no validated every-other-day ETI dose escalation protocol exists to compensate for rifampin-driven ivacaftor clearance acceleration; the labeled management of strong CYP3A4 inducers with ETI is avoidance, not dose adjustment — and managing both a tacrolimus dose increase and an ETI dose adjustment simultaneously in a post-transplant patient creates unacceptable pharmacokinetic risk.
• Option E: Option E is incorrect because rifampin's CYP3A4 induction of ivacaftor is not moderate — it is labeled as a contraindication requiring avoidance; characterizing the ETI interaction as manageable with every-other-day dosing misapplies the inhibitor protocol to an inducer interaction.

ANSWER: B

Rationale:

Despite this patient's outstanding ETI response — confirmed by sweat chloride normalization, FEV1 stabilization, and elimination of pulmonary exacerbations — a new 9 mm cystic pulmonary lesion requires clinical evaluation for several reasons that are independent of CFTR functional status. CF patients carry an elevated baseline lifetime risk of pulmonary malignancy relative to the general population, attributable to decades of chronic neutrophilic airway inflammation, recurrent oxidative stress from infectious cycles, and the mutagenic cellular environment established by years of CFTR dysfunction — none of which are reversed by ETI initiation. This patient has additional independent risk factors: a 12 pack-year smoking history (a recognized independent lung cancer risk factor even in former smokers) and chronic post-transplant immunosuppression, which reduces immune cancer surveillance. ETI's pharmacological CFTR rescue — however complete as indicated by sweat chloride — does not reverse accumulated genomic damage or eliminate these structural risk factors. A new pulmonary cystic lesion in this clinical context warrants follow-up CT at a shortened interval (3 to 6 months) to assess for growth or change in character; further characterization with PET-CT or bronchoscopic evaluation should be guided by lesion behavior on follow-up imaging. The patient's excellent modulator response does not justify dismissing a new structural finding.

• Option A: Option A is incorrect because ETI-induced pulmonary cyst formation through CFTR-mediated alveolar overdistension is not an established adverse effect; no such mechanism exists in the pharmacological literature, and the stated 90% spontaneous resolution rate is fabricated.
• Option C: Option C is incorrect because normalized sweat chloride reflects CFTR function in sweat duct epithelium and does not confer immunity from lung cancer; CFTR restoration does not eliminate the oncogenic risk established by decades of prior inflammation, oxidative damage, and smoking, and the claim that CFTR-sufficient airways cannot develop primary lung cancer is pharmacologically and oncologically incorrect.
• Option D: Option D is incorrect because while prior MAC infection could produce a cavitary lesion, this patient completed a full MAC regimen and has been clinically well for 14 months; urgent bronchoscopy with empirical MAC retreatment without further structural imaging evaluation is not the appropriate first step for a new cystic lesion in a patient with multiple independent risk factors for malignancy.
• Option E: Option E is incorrect because attributing a new 9 mm lesion to a previously undetected resolving mucus plug is speculative reassurance that bypasses the need for appropriate surveillance in a patient with elevated pulmonary malignancy risk.

ANSWER: E

Rationale:

Ivacaftor is metabolized primarily by cytochrome P450 isoform CYP3A4 (CYP3A4), and voriconazole is a potent inhibitor of CYP3A4 (as well as CYP2C19 and CYP2C9). When voriconazole is co-administered with ivacaftor, CYP3A4-mediated ivacaftor metabolism is substantially blocked, causing ivacaftor plasma concentrations to rise well above the therapeutic range at the standard twice-daily 150 mg dosing schedule. The ivacaftor prescribing label specifies that when any strong CYP3A4 inhibitor is co-prescribed — including voriconazole, itraconazole, posaconazole, ketoconazole, and fluconazole at systemic doses — ivacaftor dosing frequency should be reduced to every other day for the duration of the inhibitor course. This labeled adjustment maintains therapeutic ivacaftor exposure while preventing supratherapeutic concentrations and associated adverse effects. For this patient on ivacaftor monotherapy (not ETI), the adjustment applies specifically to ivacaftor 150 mg: the drug is taken every other day rather than every 12 hours during voriconazole co-administration. The adjustment must be applied and documented at every encounter where an azole antifungal is initiated or modified.

• Option A: Option A is incorrect because a defined dose-adjustment protocol exists in the ivacaftor label for strong CYP3A4 inhibitor co-administration; complete permanent discontinuation is not required or appropriate, and tezacaftor does not eliminate the voriconazole-ivacaftor interaction — tezacaftor-ivacaftor still contains ivacaftor as its potentiator, which carries the identical CYP3A4 interaction.
• Option B: Option B is incorrect because voriconazole is also a potent CYP3A4 inhibitor — not only a CYP2C19 and CYP2C9 inhibitor — and CYP3A4 inhibition is the primary pharmacokinetic concern for ivacaftor co-administration; the claim that voriconazole does not inhibit CYP3A4 is pharmacologically incorrect.
• Option C: Option C is incorrect because the labeled management for strong CYP3A4 inhibitor co-administration is reduced dosing frequency (every other day), not reduced dose at each administration; 75 mg twice daily is not a pharmacokinetically validated or labeled dose adjustment strategy for strong inhibitor co-administration.
• Option D: Option D is incorrect because echinocandins have limited efficacy for ABPA, which requires azole antifungal therapy targeting the hypersensitivity-driven inflammatory response to Aspergillus; the clinical decision to switch antifungals must be based on therapeutic indication, and the labeled every-other-day ivacaftor adjustment is straightforward and well-characterized — it does not justify compromising ABPA treatment.

ANSWER: B

Rationale:

The pharmacological rationale for transitioning from ivacaftor monotherapy to ETI in a G551D/F508del compound heterozygote rests on what each allele contributes to CFTR dysfunction and what each modulator component addresses. Ivacaftor monotherapy effectively potentiates the G551D allele: G551D CFTR is correctly folded and traffics to the apical membrane in near-normal amounts, so the pharmacological target for ivacaftor — surface-expressed CFTR with a gating defect — is fully available, and the STRIVE trial-demonstrated 10.6 percentage-point FEV1% predicted improvement reflects this. However, the F508del allele produces CFTR that undergoes extensive ER-associated degradation (ERAD) through the Hsp70/Hsp90 quality control machinery and reaches the apical membrane in negligible quantities without corrector assistance; ivacaftor applied to the F508del allele without corrector pre-treatment has essentially no surface-expressed F508del CFTR to potentiate, and the pharmacological contribution from this allele on ivacaftor alone is minimal. By adding elexacaftor and tezacaftor — two CFTR correctors with distinct binding sites that cooperatively stabilize F508del CFTR in the ER and reduce ERAD — ETI rescues a substantially greater amount of F508del CFTR to traffic to the apical membrane. Ivacaftor then potentiates both the corrected F508del CFTR and the already-surface-expressed G551D CFTR simultaneously, generating greater total airway chloride transport than potentiation of the G551D allele alone. This dual-allele benefit is the pharmacological basis for the clinical superiority of ETI over ivacaftor monotherapy in this genotype.

• Option A: Option A is incorrect because the corrector components of ETI do not add potentiation to the G551D allele — they rescue F508del CFTR trafficking; the correctors address the processing defect of the F508del allele, providing a pharmacological benefit that ivacaftor alone cannot achieve, and this benefit is not redundant.
• Option C: Option C is incorrect because ETI does not contain a pharmacologically superior ivacaftor formulation — the ivacaftor component of ETI is the same drug; the rationale for ETI over monotherapy is the addition of correctors rescuing the F508del allele, not an enhanced ivacaftor pharmacokinetic profile.
• Option D: Option D is incorrect because corrector therapy does provide meaningful rescue of the F508del allele in compound heterozygotes, as demonstrated by clinical trial data in this exact genotypic category; the F508del allele is not pharmacologically inert — it represents half the patient's CFTR gene output with a correctable processing defect.
• Option E: Option E is incorrect because there is no FDA mandate requiring transition from ivacaftor monotherapy to ETI within a fixed timeframe; the preference for ETI over ivacaftor monotherapy in eligible compound heterozygotes is based on pharmacological benefit from rescuing the F508del allele, not on a regulatory transition mandate.

ANSWER: D

Rationale:

The rifampin-ETI pharmacokinetic interaction is identical in mechanism and clinical consequence to the rifampin-ivacaftor monotherapy interaction because the critical CYP3A4 substrate in both cases is ivacaftor — the potentiator component shared by both regimens. Rifampin is a potent inducer of CYP3A4, the primary enzyme responsible for ivacaftor hepatic metabolism, regardless of whether ivacaftor is administered as monotherapy or as part of a fixed-dose combination with tezacaftor and elexacaftor. Rifampin-driven CYP3A4 induction markedly accelerates ivacaftor metabolism, reducing ivacaftor plasma concentrations to potentially sub-therapeutic levels in both formulations. The ETI prescribing label — like the ivacaftor prescribing label — explicitly classifies rifampin among the strong CYP3A4 inducers that should be avoided with any ivacaftor-containing regimen. The presence of elexacaftor and tezacaftor in the combination does not protect ivacaftor from rifampin-driven clearance acceleration; these correctors act upstream at the ER level on CFTR protein and have no pharmacokinetic interaction with ivacaftor's CYP3A4 metabolism. The correct management is therefore identical to what was appropriate when she was on ivacaftor monotherapy: a rifampin-free MAC regimen using azithromycin, ethambutol, and amikacin, with specialist guidance on regimen selection for MAC in the context of CFTR modulator therapy.

• Option A: Option A is incorrect because tezacaftor and elexacaftor do not competitively inhibit the CYP3A4 active site; they are not CYP3A4 inhibitors and provide no buffering of rifampin's induction effect on ivacaftor clearance.
• Option B: Option B is incorrect because the rifampin-ivacaftor interaction is not restricted to ivacaftor monotherapy — it applies to ivacaftor in all formulations; the pharmacokinetic optimization of the ETI corrector-to-potentiator ratio does not protect the ivacaftor component from CYP3A4 induction, and no such "formulation buffering" mechanism exists.
• Option C: Option C is incorrect because elexacaftor does not induce its own CYP3A4 metabolism through autoinduction; autoinduction is not an established property of elexacaftor, and the combination is not described as absolutely contraindicated under all circumstances in the label — it is characterized as a drug to avoid, with the correct management being regimen substitution.
• Option E: Option E is incorrect because the twice-daily ivacaftor dosing schedule in ETI does not provide pharmacokinetic protection against rifampin-induced trough concentration reductions; CYP3A4 induction is a continuous enzymatic effect on hepatic clearance that operates throughout the dosing interval regardless of dosing frequency, and monitoring sweat chloride weekly does not adequately manage an interaction that eliminates therapeutic drug exposure.

ANSWER: A

Rationale:

Azithromycin's CYP3A4 interaction profile is distinctly different from other macrolide antibiotics — particularly erythromycin and clarithromycin — that are clinically significant CYP3A4 inhibitors. Erythromycin and clarithromycin exert their CYP3A4 inhibition through formation of stable metabolite-intermediate (MI) complexes with the CYP3A4 heme iron, producing quasi-irreversible enzyme inhibition that substantially raises plasma concentrations of CYP3A4 substrates including ivacaftor. Azithromycin does not form these MI complexes to a clinically significant degree due to its distinctive structural features (an azalide with a nitrogen-containing ring), and its clinical CYP3A4 inhibitory potency at the doses and frequencies used in MAC therapy — 500 mg three times weekly — is negligible. Clinical pharmacokinetic studies confirm that azithromycin does not produce meaningful increases in the exposure of CYP3A4 substrates at these doses. This patient's stable sweat chloride of 29 mmol/L and FEV1 of 83% after 3 months of concurrent MAC therapy confirm that CFTR potentiation by ivacaftor is maintained without compromise, consistent with the absence of clinically relevant CYP3A4 inhibition by azithromycin. ETI continues at standard daily dosing without any dose adjustment requirement for azithromycin co-administration.

• Option B: Option B is incorrect because azithromycin is not a strong CYP3A4 inhibitor equivalent to clarithromycin; the every-other-day ETI adjustment is reserved for strong CYP3A4 inhibitors such as azole antifungals, and azithromycin does not meet this threshold; the interpretation that stable biomarkers indicate undetected supratherapeutic ivacaftor toxicity contradicts the pharmacokinetic evidence.
• Option C: Option C is incorrect because not all macrolides are classified as strong CYP3A4 inhibitors — azithromycin specifically is distinguished from erythromycin and clarithromycin by its lack of significant MI complex formation; FDA classification as strong CYP3A4 inhibitor applies to clarithromycin and erythromycin, not azithromycin; and the proposed alternate-day adjustment protocol has no pharmacokinetic basis for intermittent dosing of a drug that does not significantly inhibit CYP3A4.
• Option D: Option D is incorrect because azithromycin is not a moderate CYP3A4 inhibitor producing 30 to 40% ivacaftor concentration increases; its CYP3A4 inhibitory activity is negligible at MAC therapy doses, and no label-based dose adjustment of the ETI morning tablet on azithromycin days is warranted or established.
• Option E: Option E is incorrect because azithromycin does not cause irreversible heme N-alkylation of CYP3A4; this mechanism is not characteristic of any macrolide antibiotic used in clinical practice; the described progressive ivacaftor accumulation and 2-week washout protocol are fabricated.

ANSWER: C

Rationale:

The oral glucose tolerance test (OGTT) — measuring fasting plasma glucose and plasma glucose 2 hours after a standardized 75-gram oral glucose load — is the recommended and validated diagnostic test for CF-related diabetes (CFRD) per CF clinical guidelines. CFRD characteristically presents with postprandial hyperglycemia before fasting hyperglycemia because progressive pancreatic islet destruction from exocrine fibrosis preferentially impairs the insulin secretory response to glucose loads while partially sparing basal insulin secretion in earlier stages. HbA1c is systematically unreliable as a diagnostic or monitoring tool in CF patients for a well-established mechanistic reason: CF is associated with increased red blood cell (RBC) turnover attributable to chronic systemic inflammation from recurrent pulmonary infections, oxidative stress from neutrophilic airway disease, nutritional deficiencies, and hemolytic contributions — all of which shorten erythrocyte lifespan below the normal approximately 120-day average. Because HbA1c reflects the cumulative glycosylation of hemoglobin over the lifetime of the circulating red cell, shorter erythrocyte survival means less time for glucose to glycosylate hemoglobin, producing HbA1c values that are systematically lower than the true average glucose exposure over the preceding 2 to 3 months. An HbA1c of 5.6% in a CF patient with symptoms of weight loss, polydipsia, and postprandial fatigue cannot be used to exclude CFRD; OGTT must be performed. This patient's F508del/W1282X genotype means ETI is rescuing her F508del allele — the W1282X allele receives no pharmacological benefit — and the residual CF-related pancreatic disease from both alleles' cumulative CFTR dysfunction makes CFRD a real risk.

• Option A: Option A is incorrect because HbA1c is specifically unreliable in CF and a value of 5.6% does not exclude CFRD; ivacaftor's adverse effects do not include the constellation of weight loss, polydipsia, and postprandial fatigue this patient describes, and attributing symptoms to a fabricated ivacaftor motility effect without CFRD investigation is clinically inappropriate.
• Option B: Option B is incorrect because no CF-specific HbA1c threshold of 5.7% exists as a diagnostic cutoff; CF clinical guidelines specifically recommend OGTT rather than HbA1c thresholds for CFRD diagnosis because HbA1c is unreliable in this population at any threshold.
• Option D: Option D is incorrect because fasting plasma glucose is less sensitive than OGTT for detecting early CFRD, which characteristically presents with postprandial rather than fasting glucose dysregulation; relying on fasting glucose alone with the stated exclusion criteria would systematically miss early CFRD.
• Option E: Option E is incorrect because ETI-mediated improvement in pancreatic ductal bicarbonate secretion does not alter red blood cell intracellular pH or the rate of hemoglobin glycation in a clinically meaningful way; the mechanism of HbA1c unreliability in CF is increased RBC turnover from inflammation and nutritional compromise, not ETI pharmacology; and continuous glucose monitoring while useful clinically is not the validated replacement for OGTT as the primary diagnostic standard for CFRD.

ANSWER: E

Rationale:

CF-related diabetes (CFRD) has a pathophysiology that is fundamentally distinct from type 2 diabetes mellitus. In CF, progressive exocrine pancreatic fibrosis — driven by the accumulation of inspissated secretions from defective CFTR-mediated ductal bicarbonate and fluid secretion — destroys both the exocrine acinar cells responsible for digestive enzyme production and the endocrine islet cells interspersed within the pancreatic parenchyma, including insulin-secreting beta cells. The result is relative insulin deficiency: the pancreas cannot secrete sufficient insulin to meet physiological demands, particularly during the postprandial period. This is categorically different from type 2 diabetes mellitus, where the primary defect is peripheral tissue insulin resistance with compensatory hyperinsulinemia in early stages. Metformin acts primarily by activating AMP-activated protein kinase (AMPK) in hepatocytes, reducing hepatic gluconeogenesis and improving insulin sensitivity in peripheral tissues — mechanisms targeted at insulin resistance, which is not the dominant defect in CFRD. Insulin therapy directly replaces the deficient hormone, corrects the primary pathophysiological defect, and — critically in this nutritionally compromised patient who has lost weight and has a BMI of 18.3 kg/m² — may provide anabolic benefit by promoting protein synthesis and reducing muscle catabolism, improving both glycemic control and nutritional outcomes. Insulin therapy is the guideline-recommended first-line treatment for CFRD and should not be deferred pending failure of oral therapy.

• Option A: Option A is incorrect because CFRD is not pathophysiologically identical to type 2 diabetes mellitus; the primary defect is insulin deficiency from islet destruction, not peripheral insulin resistance; and deferring insulin until HbA1c exceeds 8.0% delays appropriate treatment in a nutritionally vulnerable patient.
• Option B: Option B is incorrect because metformin is not significantly impaired by CF-related fat malabsorption; metformin is a water-soluble drug absorbed by active transport in the small intestinal epithelium and does not require lipase or bile salts for absorption; the premise that CF malabsorption prevents metformin bioavailability is pharmacologically incorrect.
• Option C: Option C is incorrect because CFRD is not caused by autoimmune T-cell-mediated islet destruction — that is the mechanism of type 1 diabetes mellitus; CFRD results from mechanical islet destruction by progressive pancreatic fibrosis, a completely different pathophysiological mechanism.
• Option D: Option D is incorrect because inhaled tobramycin achieves minimal systemic absorption and does not produce systemic aminoglycoside concentrations sufficient to inhibit OCT2-mediated metformin renal elimination; this proposed drug interaction is not an established clinical concern.

ANSWER: A

Rationale:

The diurnal glucose pattern — acceptable fasting morning values with marked postprandial hyperglycemia at lunch and dinner — reflects the pharmacokinetic and pharmacodynamic profile of prednisone superimposed on the underlying insulin deficiency of CFRD. Prednisone is typically administered as a morning dose; its plasma concentration peaks in the late morning to early afternoon and remains elevated into the evening before declining overnight. Glucocorticoids produce dose-dependent insulin resistance through multiple mechanisms: they impair post-receptor insulin signaling by reducing insulin receptor substrate (IRS) phosphorylation, suppressing GLUT4 transporter expression and translocation in skeletal muscle and adipose tissue, and stimulating hepatic gluconeogenesis while impairing insulin's ability to suppress hepatic glucose output. These effects produce maximal insulin resistance in the afternoon and evening — corresponding to the peak and plateau of prednisone plasma concentrations — which explains why midday and dinner glucose readings are most severely elevated while fasting morning readings, which occur during the prednisone trough, remain relatively preserved. The correct insulin adjustment strategy prioritizes increasing prandial (rapid-acting) insulin at lunch and dinner — where the steroid-induced insulin resistance peaks — and adding correction doses for postprandial hyperglycemia. Basal insulin may also need upward adjustment. Close glucose monitoring throughout the day is essential, and insulin doses should be tapered back down as prednisone is weaned to prevent hypoglycemia during the taper. This pattern of steroid-induced hyperglycemia is well-recognized in CFRD clinical management.

• Option B: Option B is incorrect because ivacaftor is not metabolized to a glucocorticoid receptor agonist byproduct at any plasma concentration, and ETI does not require interruption during prednisone therapy; holding ETI during a pulmonary exacerbation in a patient who benefits from CFTR rescue is clinically counterproductive.
• Option C: Option C is incorrect because the diurnal glucose pattern — preserved fasting glucose with severe postprandial hyperglycemia — on day 2 of prednisone is temporally and pharmacokinetically consistent with steroid-induced insulin resistance, not a coincident natural disease progression; attributing corticosteroid-induced hyperglycemia to disease progression without addressing the pharmacological cause is clinically incorrect.
• Option D: Option D is incorrect because tobramycin does not cause acute pancreatitis, and acute pancreatitis does not cause a transient insulin hypersecretion phase requiring insulin to be held; this mechanism is fabricated and the clinical recommendation to hold insulin in a hyperglycemic patient is dangerous.
• Option E: Option E is incorrect because prednisone does not downregulate CFTR gene transcription in a clinically meaningful way that acutely worsens exocrine fibrosis-driven CFRD pathophysiology; the mechanism of steroid-induced hyperglycemia is peripheral insulin resistance and hepatic gluconeogenesis stimulation, not acute CFTR transcriptional suppression.

ANSWER: D

Rationale:

The insulin resistance produced by systemic glucocorticoids is dose-dependent: higher prednisone doses produce greater insulin resistance, and this relationship is pharmacodynamically proportional across clinically used dose ranges. As prednisone is tapered from 40 mg to 20 mg to 10 mg, the insulin resistance effect diminishes in a stepwise, dose-proportional manner. If insulin doses that were appropriate at the 40 mg prednisone level are maintained unchanged as prednisone is reduced, the declining glucocorticoid-driven insulin resistance progressively creates a mismatch between the elevated insulin doses and the diminishing insulin resistance — generating increasing hypoglycemia risk, particularly at mealtimes when prandial insulin doses are highest. The correct management strategy is therefore to reduce prandial insulin doses progressively and in parallel with each prednisone dose reduction step, using point-of-care glucose monitoring before and 2 hours after meals at each taper step to guide the pace and magnitude of insulin reduction. Prandial (rapid-acting) insulin doses typically require more aggressive downward adjustment during the taper than basal insulin, because the postprandial hyperglycemia pattern that prednisone produces (and that drove the initial prandial dose escalation) resolves more rapidly and completely as prednisone plasma concentrations fall. Basal insulin requirements normalize more gradually and should be tapered more conservatively. The target is to return to approximately pre-hospitalization insulin doses as prednisone reaches physiological or sub-physiological levels, with glucose monitoring confirming adequacy at each step.

• Option A: Option A is incorrect because glucocorticoid receptor downregulation does not maintain insulin resistance for 2 weeks after prednisone discontinuation in the manner described; insulin resistance from glucocorticoids resolves relatively promptly as prednisone plasma concentrations decline during tapering and after discontinuation; maintaining prednisone-adjusted insulin doses for 2 weeks post-taper would cause significant hypoglycemia.
• Option B: Option B is incorrect because glucocorticoid-induced insulin resistance is dose-dependent and graded across the therapeutic range — it is not an all-or-nothing phenomenon; 10 mg of prednisone produces substantially less insulin resistance than 40 mg, and the insulin doses adjusted for 40 mg would cause hypoglycemia at the 10 mg taper level.
• Option C: Option C is incorrect because while it correctly identifies the strategy of parallel stepwise reduction with glucose monitoring, it fails to distinguish that basal insulin should be tapered more conservatively than prandial insulin, applying the same taper pace to both inappropriately; option D provides the more complete and accurate management description that accounts for this clinically important distinction.
• Option E: Option E is incorrect because simultaneously discontinuing all prednisone-adjusted insulin doses with the final prednisone dose creates an abrupt large insulin dose reduction that bypasses the stepwise monitoring approach needed to confirm glycemic adequacy; moreover, insulin requirements do not disappear instantaneously with the last prednisone dose — they diminish progressively across the taper and for a brief period after the last dose, and a stepwise guided approach is safer than simultaneous discontinuation.

ANSWER: B

Rationale:

Chest tightness, worsening dyspnea, and acute FEV1 decline within the first days of lumacaftor-ivacaftor initiation are a recognized and labeled respiratory adverse effect specific to lumacaftor-containing regimens. This adverse effect occurs across the treated population but is most frequent and clinically significant in patients with more advanced baseline lung disease — particularly those with FEV1% predicted below 40% — where the risk of severe respiratory deterioration after lumacaftor-ivacaftor initiation is highest. This patient's baseline of 36% places her squarely in the highest-risk group. The mechanism is incompletely understood but is distinct from infectious exacerbation: the absence of fever, unchanged sputum cultures from 3 weeks prior, and the temporal relationship to lumacaftor-ivacaftor day 4 initiation all support a drug-related adverse effect rather than a new infection. The appropriate management is to hold lumacaftor-ivacaftor while respiratory symptoms are evaluated, allow the FEV1 to recover, and then make a specialist-guided decision about rechallenge (sometimes with pre-treatment bronchodilators or gradual dose escalation) or transition to an alternative regimen — ideally ETI when available, which does not share lumacaftor's respiratory adverse effect profile because neither tezacaftor nor elexacaftor produces this toxicity.

• Option A: Option A is incorrect because lumacaftor's CYP3A4 induction does not meaningfully reduce inhaled corticosteroid plasma concentrations at standard inhaled doses, and worsening airway inflammation from this mechanism is not the established cause of acute lumacaftor-ivacaftor respiratory adverse events; treating with intravenous antibiotics and continuing the drug while the patient has acute lumacaftor-related respiratory deterioration is inappropriate management.
• Option C: Option C is incorrect because acute FEV1 decline from mucus mobilization causing temporary central airway obstruction is not an established mechanism of the lumacaftor-ivacaftor respiratory adverse effect; this teleological explanation is not supported by pharmacological evidence, and continuing the drug at full dose during acute respiratory deterioration is unsafe.
• Option D: Option D is incorrect because ivacaftor is a CFTR potentiator and does not exert paradoxical M3 muscarinic agonism; the respiratory adverse effect is specific to lumacaftor, and there is no established protocol of ipratropium pre-treatment that reliably prevents the adverse effect and allows full-dose continuation.
• Option E: Option E is incorrect because IgE-mediated hypersensitivity to lactose in tablet formulations is exceedingly rare and the clinical presentation described — progressive dyspnea and FEV1 decline over days rather than acute anaphylaxis within minutes of the first dose — is not consistent with IgE-mediated bronchoconstriction.

ANSWER: D

Rationale:

Lumacaftor is a potent inducer of cytochrome P450 isoform CYP3A4 (CYP3A4), the primary enzyme responsible for hepatic and intestinal metabolism of the steroid hormones used in combined oral contraceptives: ethinyl estradiol (an estrogen) and progestin components such as levonorgestrel, norethindrone, and etonogestrel. By substantially upregulating CYP3A4 expression and activity, lumacaftor markedly accelerates the first-pass and systemic metabolism of both hormone components, reducing their plasma concentrations to levels that may be insufficient to maintain reliable contraceptive efficacy. This interaction is explicitly addressed in the lumacaftor-ivacaftor prescribing label, which states that hormonal contraceptive efficacy may be reduced and recommends that patients use an effective non-hormonal contraceptive method while on lumacaftor-containing regimens. This patient must be counseled promptly that her combined oral contraceptive pill has likely been unreliable since lumacaftor-ivacaftor was started, and she should immediately begin using a non-hormonal method — a copper intrauterine device, condoms with spermicide, or abstinence — for the entire duration of any lumacaftor-containing therapy. This interaction does not apply to tezacaftor-ivacaftor or ETI because tezacaftor and elexacaftor do not induce CYP3A4, making them pharmacologically safer for patients on hormonal contraception.

• Option A: Option A is incorrect because lumacaftor's hormonal contraceptive interaction is mediated by CYP3A4 enzyme induction, not by P-glycoprotein efflux; switching to a patch or vaginal ring delivers hormone via the transdermal or vaginal route but does not bypass hepatic CYP3A4, and lumacaftor's systemic enzyme induction affects hormone metabolism regardless of the administration route.
• Option B: Option B is incorrect because lumacaftor does not exhibit a biphasic inhibitory-then-inductive effect on CYP3A4; its pharmacological interaction is CYP3A4 induction from the initiation of therapy, not initial inhibition followed by induction, and there is no initial window of enhanced contraceptive efficacy.
• Option C: Option C is incorrect because the lumacaftor-CYP3A4 induction interaction with hormonal contraceptives is a clinically confirmed and labeled pharmacokinetic interaction, not a theoretical in vitro finding without clinical evidence; the label explicitly recommends non-hormonal contraception.
• Option E: Option E is incorrect because CYP3A4 metabolizes both estrogens and progestins — the induction is not selective for progestins — and increasing progestin formulation does not adequately compensate for CYP3A4-driven accelerated progestin metabolism.

ANSWER: C

Rationale:

ETI is pharmacologically superior to lumacaftor-ivacaftor for this patient on two independent and important grounds. First, neither elexacaftor nor tezacaftor — the corrector components of ETI — induces CYP3A4. This eliminates the contraceptive interaction that made lumacaftor-ivacaftor problematic: combined oral contraceptives are metabolized by CYP3A4, and lumacaftor's potent CYP3A4 induction accelerates their metabolism to sub-therapeutic concentrations. Because ETI's correctors do not induce CYP3A4, combined oral contraceptive hormone concentrations are not affected, and this patient can safely use hormonal contraception if she chooses while on ETI. Second, the lumacaftor-specific respiratory adverse effect — chest tightness and acute FEV1 decline particularly in patients with FEV1% predicted below 40% — is not associated with tezacaftor or elexacaftor. The respiratory adverse effect appears to be specific to lumacaftor's pharmacological properties and is eliminated by transitioning to ETI. In addition to resolving both adverse effects, ETI provides superior F508del CFTR rescue compared with lumacaftor-ivacaftor: elexacaftor and tezacaftor bind to distinct sites on the misfolded F508del CFTR protein simultaneously, producing cooperative conformational stabilization substantially greater than either corrector alone and greater than lumacaftor alone, resulting in far more F508del CFTR trafficking to the apical membrane and greater clinical benefit.

• Option A: Option A is incorrect because elexacaftor is not a CYP3A4 inhibitor and does not have bronchodilatory properties; the net CYP3A4 effect of ETI is not inhibitory, and the described mechanism of elexacaftor preventing contraceptive failure is pharmacologically fabricated.
• Option B: Option B is incorrect because tezacaftor and elexacaftor do not induce CYP3A4 more potently than lumacaftor — they do not induce CYP3A4 at all; and the described mechanism of induction producing paradoxically higher estrogen bioavailability through intestinal CFTR bicarbonate upregulation is physiologically unfounded.
• Option D: Option D is incorrect because the total daily ivacaftor dose difference between ETI and lumacaftor-ivacaftor is not the basis for ETI's superiority in either avoiding the respiratory adverse effect or reducing the CYP3A4 interaction; ivacaftor does not have CFTR-independent anti-inflammatory eosinophil effects, and the ivacaftor dose difference is not the key pharmacological distinction.
• Option E: Option E is incorrect because no FDA regulatory mandate restricting lumacaftor-ivacaftor specifically in patients with respiratory adverse effects or on combined oral contraceptives exists; the preference for ETI is based on pharmacological and clinical grounds, not a regulatory prohibition.

ANSWER: E

Rationale:

The ETI prescribing label specifies two distinct hepatotoxicity thresholds for drug interruption: ALT or AST exceeding five times the upper limit of normal (ULN) in the absence of hepatotoxicity symptoms, or exceeding three times the ULN in the presence of symptoms (jaundice, right upper quadrant pain, nausea). This patient has ALT at 5.8 times the ULN and AST at 5.1 times the ULN — both exceeding the five times ULN asymptomatic interrupt threshold — in the complete absence of hepatotoxicity symptoms. Both laboratory values meet the labeled criterion for drug interruption. ETI should therefore be interrupted immediately, and LFTs monitored at regular intervals (weekly or twice weekly) until values begin to decline. Once LFTs normalize or substantially improve, a specialist-guided decision about ETI rechallenge — potentially with more frequent monitoring, dose escalation protocols, or specialist hepatology input — or permanent discontinuation should be made based on the pace of LFT recovery and the clinical risk-benefit assessment for this patient. If rechallenge is attempted and LFTs re-elevate, permanent discontinuation is warranted.

• Option A: Option A is incorrect because 10 times the ULN is not the labeled asymptomatic interrupt threshold for ETI; the labeled threshold is five times the ULN without symptoms, which this patient has already met at 5.8 times the ULN; the 10 times the ULN figure is not an established ETI management threshold.
• Option B: Option B is incorrect because the labeled threshold for asymptomatic interruption is five times the ULN, not three times the ULN without symptoms; three times the ULN is the threshold with symptoms; moreover, permanent discontinuation and liver biopsy as first-line management of asymptomatic transaminase elevation meeting the interrupt threshold is premature — rechallenge evaluation after LFT normalization is a standard clinical consideration.
• Option C: Option C is incorrect because every-other-day dosing is the labeled protocol for managing strong CYP3A4 inhibitor co-administration, not for managing ETI-associated hepatotoxicity; dose reduction to every-other-day is not an established management strategy for transaminase elevations, and the label specifies interruption, not dose reduction, for this situation.
• Option D: Option D is incorrect because while CF-related liver disease can elevate baseline LFTs, ALT rising to 5.8 times the ULN in a patient on a drug with a known hepatotoxicity adverse effect profile and a labeled interrupt threshold requires drug interruption per labeling — attributing the elevation to CF hepatopathy without first interrupting the drug and evaluating the LFT trend is not the appropriate management of a labeled hepatotoxicity signal.

ANSWER: A

Rationale:

Both G542X and W1282X are class I CFTR mutations — nonsense mutations that introduce premature stop codons into the CFTR mRNA and trigger nonsense-mediated mRNA decay (NMD), a cellular RNA surveillance mechanism that degrades mRNAs containing premature stop codons to prevent the production of truncated dominant-negative or otherwise harmful proteins. The result is absent or severely truncated CFTR protein with no functional channel at the apical epithelial membrane. This absence of the pharmacological target eliminates the rationale for any approved CFTR modulator: CFTR correctors (lumacaftor, tezacaftor, elexacaftor) require the presence of a misfolded but translatable CFTR protein in the endoplasmic reticulum to stabilize and rescue — there is no such protein when NMD has eliminated the mRNA. CFTR potentiators (ivacaftor) require surface-expressed CFTR channels to increase the open probability of — without any functional channel at the membrane, potentiation has no target. Management must rely entirely on best supportive care: aggressive airway clearance therapy, inhaled dornase alfa to reduce mucus viscosity, inhaled hypertonic saline to hydrate airway surface liquid, prompt antibiotic treatment of pulmonary exacerbations, nutritional optimization with pancreatic enzyme replacement and fat-soluble vitamin supplementation, and proactive discussion of clinical trial enrollment in investigational class I therapies (read-through agents, RNA-targeted approaches, nonsense suppression strategies). With FEV1% predicted now at 28% on a sharply declining trajectory, lung transplant referral and evaluation is a priority clinical action.

• Option B: Option B is incorrect because there is no FDA compassionate use or expanded access pathway for ETI in class I homozygotes based on low FEV1; ETI has no pharmacological rationale or regulatory basis in patients with no F508del allele, and automatic authorization does not exist for this indication.
• Option C: Option C is incorrect because W1282X is a class I nonsense mutation — NMD eliminates the mRNA before meaningful truncated protein reaches the apical membrane in amounts that respond to ivacaftor potentiation; a routine clinical ivacaftor trial for W1282X homozygotes is not standard of care and is not guideline-supported.
• Option D: Option D is incorrect because no FDA label expansion has designated W1282X as a residual function mutation for tezacaftor-ivacaftor eligibility based on NPD testing; this reclassification does not exist in current labeling, and NPD testing is a research tool not used for clinical modulator eligibility determination.
• Option E: Option E is incorrect because ataluren (PTC124) does not have FDA approval for CF in the United States; its phase 3 trials did not meet primary endpoints and it failed to gain FDA approval for any indication in the US; compassionate use access through a documented US expanded access program does not exist for this agent in CF.

ANSWER: C

Rationale:

With FEV1% predicted at 28% and an annual decline rate of approximately 6.5 percentage points per year over 24 months, this patient has entered the range where active lung transplant evaluation is a clinical priority. Widely recognized CF transplant referral criteria — based on international CF consensus guidelines and ISHLT (International Society for Heart and Lung Transplantation) guidance — include FEV1% predicted below 30%, FEV1 decline of 20% or greater relative value over 12 months, worsening hypoxemia, hypercapnia, or pulmonary hypertension, and rapid clinical deterioration despite maximal therapy. This patient meets multiple criteria: absolute FEV1% predicted of 28%, a 13-percentage-point absolute decline over 24 months, bilateral severe bronchiectasis, and chronic colonization with treatment-refractory organisms. Critically, this patient has no approved disease-modifying pharmacological option — no CFTR modulator can alter his disease trajectory — making the transplant pathway the only available intervention that can substantially change his prognosis. Referral should occur before the patient's clinical condition deteriorates further, as very low FEV1, significant deconditioning, active infection, or severe nutritional compromise can preclude candidacy. Earlier referral allows comprehensive evaluation, pre-transplant optimization of nutritional status and exercise capacity, and time for the evaluation process to complete before the transplant window closes.

• Option A: Option A is incorrect because an absolute FEV1% predicted threshold of 20% as the referral trigger is not consistent with current CF transplant referral guidelines, which recommend referral when FEV1% predicted falls below 30% combined with other risk factors including rapid decline; waiting until FEV1 reaches 20% in a patient declining at 6.5 percentage points per year risks missing the referral window entirely.
• Option B: Option B is incorrect because azithromycin has not demonstrated a 35% reduction in FEV1 decline in class I mutation CF patients in clinical trials; while azithromycin has immunomodulatory benefits in CF exacerbation reduction, its use does not constitute a disease-modifying intervention that justifies deferring transplant listing evaluation.
• Option D: Option D is incorrect because Stenotrophomonas maltophilia colonization is not an absolute contraindication to lung transplantation at all major CF transplant centers; transplant eligibility decisions for patients with this organism are center-dependent and are assessed individually based on organism susceptibility profiles, clinical burden, and center experience.
• Option E: Option E is incorrect because while 6-minute walk test distance is an important pre-transplant assessment tool and prognostic marker, it is not the sole or primary trigger for transplant referral in CF; spirometry decline below established thresholds is a primary referral indicator in CF guidelines.

ANSWER: E

Rationale:

Investigational nonsense suppression (read-through) agents represent a mechanistically distinct approach to class I CFTR mutations that is fundamentally different from approved CFTR correctors and potentiators. In class I mutations such as G542X and W1282X, premature stop codons trigger nonsense-mediated mRNA decay (NMD), which degrades the aberrant mRNA before meaningful CFTR protein can be produced. The pharmacological target for approved correctors (misfolded CFTR protein in the ER) and potentiators (surface-expressed CFTR channels) is therefore absent. Read-through agents — including aminoglycoside antibiotics (gentamicin, tobramycin at systemic concentrations) and small-molecule read-through compounds — promote ribosomal read-through of premature stop codons by destabilizing or accommodating near-cognate aminoacyl-tRNAs at the premature stop codon position, causing the ribosome to insert an amino acid rather than terminate translation. This produces a partial-length or near-full-length CFTR protein that was absent or severely truncated without treatment, creating a pharmacological target where none previously existed. The read-through product — while containing an amino acid substitution at the original premature stop codon site — may retain sufficient structural integrity to fold, traffic, and function as a chloride channel; the residual gating function of the resulting CFTR protein would then be amenable to potentiation by ivacaftor, making a read-through agent plus ivacaftor combination conceptually rational for class I mutations. This approach is fundamentally upstream of both correctors and potentiators: it addresses the primary problem of absent CFTR protein rather than rescuing a misfolded one or increasing the activity of a surface-expressed one.

• Option A: Option A is incorrect because nonsense suppression agents do not act as CFTR correctors stabilizing misfolded ER-retained protein; the class I mutation problem is absent protein from NMD, not misfolded protein — there is no truncated protein in the ER to stabilize as correctors do with F508del.
• Option B: Option B is incorrect because read-through agents act at the ribosome during translation to suppress premature termination — not by blocking NMD without affecting translation; the statement that spontaneous amino acid insertion occurs at 60 to 70% frequency without pharmacological intervention mischaracterizes the mechanism, and the resulting protein does require potentiation for gating function.
• Option C: Option C is incorrect because CYP3A4 does not metabolize mRNA; mRNA stability is regulated by RNA surveillance pathways in the cytoplasm, not by CYP450 enzymes; this mechanism is pharmacologically fabricated.
• Option D: Option D is incorrect because Upf1 helicase inhibition and ribosomal frameshifting are two distinct and unrelated mechanisms; frameshift products from premature stop codons would be severely truncated at out-of-frame codons downstream, not near-full-length functional proteins; this description conflates and misrepresents established molecular biology.

ANSWER: B

Rationale:

The mechanistic rationale for administering dornase alfa before HFCWO vest therapy rests on the temporal relationship between enzymatic DNA cleavage and subsequent mechanical mucus mobilization. Dornase alfa (recombinant human DNase I) cleaves the high-molecular-weight extracellular DNA polymer network within CF airway mucus — released by lysed neutrophils during chronic infection — that dramatically increases mucus viscosity and adhesion to airway walls. When dornase alfa is inhaled before vest therapy, it begins enzymatic DNA cleavage during the interval between inhalation and the onset of mechanical clearance (optimally 30 to 60 minutes). By the time HFCWO is applied, the DNA polymer network has been partially degraded and mucus viscosity reduced, allowing the oscillatory airflow waves generated by the vest to more effectively dislodge mucus from airway walls and propel it toward the central airways for expectoration. Applying dornase alfa after vest therapy means the drug acts on mucus that has already been mechanically cleared as much as possible without pharmacological pre-treatment, reducing the synergistic benefit. Hypertonic saline provides osmotic hydration of the airway surface liquid layer by drawing water from airway wall tissue, which improves mucociliary transport and reduces mucus adhesiveness; this benefit is provided at any point in the sequence, but administering it before the vest maximizes the period during which the hydrated, less-adhesive mucus is available for mechanical mobilization during the vest session.

• Option A: Option A is incorrect because the rationale for hypertonic saline timing described — osmotic benefit only when applied to centrally pooled mucus after mechanical clearance — is mechanistically incorrect; hypertonic saline acts across the airway surface to hydrate the periciliary liquid layer, and this osmotic effect is clinically beneficial throughout the mucus distribution, not only in central airways.
• Option C: Option C is incorrect because the mechanistic argument for vest-first therapy does not hold for dornase alfa: the DNA-mediated viscosity of mucus is not reduced by mechanical vest therapy alone, and vest-first application does not improve pharmacological penetration of dornase alfa into the mucus layer; the evidence and mechanistic rationale favor dornase alfa before vest therapy.
• Option D: Option D is incorrect because dornase alfa and hypertonic saline should not be mixed in the same nebulizer cup — hypertonic saline is hyperosmolar and may alter the pH and ionic environment in ways that reduce dornase alfa enzymatic activity; the agents should be administered separately, and no clinical evidence supports concurrent mixed nebulization as superior to sequential administration.
• Option E: Option E is incorrect because the sequencing of mucoactive agents relative to HFCWO vest does have an established mechanistic rationale supported by clinical pharmacology evidence and CF clinical practice guidelines, and is not clinically interchangeable; administering dornase alfa before rather than after vest therapy is recommended for the mechanistic reasons described.

ANSWER: D

Rationale:

Dornase alfa (recombinant human DNase I) cleaves the phosphodiester backbone of extracellular DNA released by lysed neutrophils in chronically infected CF airways, reducing the viscosity and stiffness of the mucus gel through a mechanism entirely independent of CFTR function. The rationale for continuing dornase alfa despite ETI-mediated CFTR rescue lies in the persistent nature of the structural disease and chronic infection that predated ETI initiation. This patient has established bilateral bronchiectasis — permanent structural airway dilation from years of CFTR dysfunction-driven infection and inflammation — and chronic Pseudomonas aeruginosa colonization that has established biofilm-based infection not eliminated by restored mucociliary clearance. The chronic neutrophilic airway inflammation associated with Pseudomonas colonization continues to produce large quantities of extracellular DNA from lysed neutrophils regardless of the degree of CFTR functional rescue, because the structural disease substrate for ongoing infection persists. ETI improves CFTR function and reduces the rate of new infections, but it does not eliminate existing bronchiectasis, chronic bacterial colonization, or the neutrophilic inflammation they sustain. Dornase alfa therefore continues to address the DNA-driven viscosity component of mucus in airways that remain structurally damaged and chronically infected after ETI initiation. The ongoing benefit should be reassessed individually over time, as some patients with excellent ETI responses and reduced exacerbation burden may eventually show reduced sputum production that changes the benefit-risk calculus for continued dornase alfa use.

• Option A: Option A is incorrect because ETI does not normalize airways to a state where bacterial colonization cannot occur; established bronchiectasis, chronic Pseudomonas colonization, and the neutrophilic inflammation they produce persist after ETI initiation, and the claim that CFTR-sufficient airways prevent extracellular DNA accumulation is not supported by clinical evidence in patients with established structural disease.
• Option B: Option B is incorrect because hypertonic saline and dornase alfa address mechanistically distinct components of CF mucus pathology — osmotic hydration versus DNA polymer cleavage — and are not interchangeable; neither is redundant with the other, and hypertonic saline alone does not substitute for dornase alfa's DNA-degrading activity.
• Option C: Option C is incorrect because there is no established distinction in dornase alfa benefit based on CFRD status; the indication is based on airway infection and inflammatory status, not on the presence of CFRD, and the proposed rationale is pharmacologically unfounded.
• Option E: Option E is incorrect because endogenous airway DNase enzymes are not meaningfully suppressed by the acidic CF airway environment or reactivated by ETI-mediated airway pH normalization in a way that substitutes for exogenous dornase alfa; this proposed mechanism is not established in the pharmacological or physiological literature.

ANSWER: B

Rationale:

Despite this patient's exceptional ETI response — sweat chloride normalization and FEV1% predicted of 58% — a new 8 mm cystic pulmonary lesion on surveillance CT requires appropriate clinical evaluation for the same reason as in any patient with elevated lung cancer risk: sweat chloride normalization reflects CFTR channel function in sweat duct epithelium and does not confer immunity from pulmonary malignancy or other structural complications. CF patients carry an elevated lifetime risk of pulmonary malignancy compared with the general population, attributable to decades of chronic neutrophilic airway inflammation, oxidative DNA damage from reactive oxygen species generated during recurrent infections, and the mutagenic cellular environment established by years of CFTR dysfunction — none of which are reversed by CFTR functional restoration. This patient has additional independent risk factors that compound her background CF-related risk: a 10 pack-year smoking history (a well-established independent lung cancer risk factor in former smokers) and decades of chronic airway disease before ETI initiation. The correct management for a new indeterminate 8 mm cystic pulmonary lesion in this high-risk context is a shortened CT follow-up interval — typically 3 to 6 months — to assess for growth, change in wall character, or development of solid components. If the lesion grows or develops solid components on follow-up, further characterization with PET-CT, bronchoscopic evaluation, or CT-guided biopsy would be considered. The patient's outstanding ETI response does not change the approach to a new indeterminate pulmonary finding.

• Option A: Option A is incorrect because new cystic lesions in well-controlled ETI-treated patients are not a recognized physiological manifestation of airway remodeling as CFTR rescue proceeds; no established evidence supports the claim that such lesions uniformly resolve at 12-month follow-up, and dismissing a new pulmonary lesion without evaluation in a patient with multiple lung cancer risk factors is clinically inappropriate.
• Option C: Option C is incorrect because attributing a new 8 mm lesion to a resolving mobilized mucus plug without evaluation is speculative reassurance; even if this were the most likely explanation, confirming resolution at a shortened interval is the responsible approach in a patient with elevated malignancy risk.
• Option D: Option D is incorrect because immediate CT-guided percutaneous biopsy is not the first step for an 8 mm incidental cystic pulmonary lesion; management guidelines for indeterminate pulmonary nodules and cysts recommend interval CT surveillance before invasive sampling for lesions without features that mandate immediate biopsy.
• Option E: Option E is incorrect because an 8 mm thin-walled cystic lesion does not have imaging characteristics pathognomonic of a healed NTM granuloma, which typically present as nodules, cavitary lesions, or tree-in-bud patterns; prioritizing NTM culture results before making an imaging follow-up decision is not the appropriate management for an indeterminate cystic lesion.

ANSWER: A

Rationale:

The clinically important pharmacokinetic distinction for this patient is that neither elexacaftor nor tezacaftor — the corrector components of ETI — induces CYP2C9 (or CYP3A4), and this pharmacological difference directly determines the warfarin interaction profile. Warfarin's anticoagulant activity is mediated primarily by S-warfarin, which is metabolized by CYP2C9; induction of CYP2C9 accelerates S-warfarin metabolism and reduces its plasma concentrations, requiring warfarin dose escalation to maintain therapeutic INR — the pharmacokinetic mechanism underlying the clinically significant warfarin-lumacaftor interaction. Lumacaftor is a broad enzyme inducer that upregulates both CYP3A4 and CYP2C9, explaining why patients on lumacaftor-ivacaftor require progressively higher warfarin doses. Because neither elexacaftor nor tezacaftor induces CYP2C9, this patient on ETI does not carry this interaction, and warfarin dose requirements are not expected to be elevated above what would be predicted for a patient not on a CFTR modulator. Standard warfarin initiation monitoring is appropriate; the anticoagulation pharmacist need not anticipate higher-than-expected warfarin dose requirements based on ETI. This distinction — that ETI spares warfarin from the CYP2C9 induction that lumacaftor produces — is an important clinical advantage of the newer corrector regimen in patients who require anticoagulation.

• Option B: Option B is incorrect because tezacaftor is not a CYP2C9 inducer; it does not reduce S-warfarin concentrations, and empirically increasing the starting warfarin dose based on a non-existent tezacaftor-CYP2C9 interaction risks over-anticoagulation and hemorrhagic complications.
• Option C: Option C is incorrect because elexacaftor is not a strong CYP2C9 inhibitor; this interaction does not exist in established pharmacology, and empirically reducing the warfarin dose based on a fabricated elexacaftor-CYP2C9 inhibition creates sub-therapeutic anticoagulation risk.
• Option D: Option D is incorrect because ivacaftor is not an established clinically significant CYP2C9 inhibitor at therapeutic plasma concentrations; no labeled warfarin dose reduction is specified in the ivacaftor or ETI prescribing information based on CYP2C9 inhibition by ivacaftor.
• Option E: Option E is incorrect because the three ETI components do not collectively induce CYP2C9 to the same degree as lumacaftor; none of the ETI components — elexacaftor, tezacaftor, or ivacaftor — is a clinically significant CYP2C9 inducer, which is precisely why ETI lacks the lumacaftor-ivacaftor warfarin interaction.

ANSWER: C

Rationale:

The ETI prescribing label specifies a defined LFT monitoring schedule: measurement before initiating ETI, at 3 months after initiation, and then annually in clinically stable patients. The labeled interrupt thresholds are: ALT or AST exceeding five times the upper limit of normal (ULN) without symptoms of hepatotoxicity, or three times the ULN with symptoms (jaundice, right upper quadrant pain, nausea, vomiting). For this patient — now 30 months into stable ETI therapy with no prior LFT elevations — the labeled annual monitoring schedule applies. However, the presence of pre-existing CF-related liver disease affecting 20% of the hepatic parenchyma justifies more frequent monitoring than the standard annual interval for a clinically stable patient. CF-related liver disease itself elevates baseline LFTs in some patients and reduces hepatic reserve, which may make this patient more susceptible to ETI-associated transaminase elevations or may make elevations from other causes — such as viral illness or other medications — more clinically significant. The labeled minimum standard (annual) represents the floor for stable patients, and clinical judgment should guide more frequent testing in patients with pre-existing hepatic vulnerability. The interrupt thresholds remain fixed at the labeled values regardless of baseline hepatic status.

• Option A: Option A is incorrect because the ETI label does not specify discontinuation of LFT monitoring after 24 months without hepatotoxicity; the labeled schedule specifies annual monitoring in stable patients as a continuous requirement, and the rationale that risk becomes negligible after 2 years without elevation is not supported by the label or established pharmacovigilance data.
• Option B: Option B is incorrect because CF-related liver disease is not a contraindication to ETI and does not require transition to lumacaftor-ivacaftor; ETI is the preferred modulator regimen for F508del homozygotes when available, and lumacaftor-ivacaftor does not have established superiority in hepatotoxicity risk for patients with CF-related liver disease — the reverse may be true given lumacaftor's own hepatotoxicity profile.
• Option D: Option D is incorrect because the standard ETI LFT monitoring schedule is not monthly for the first year, then quarterly; the labeled schedule is baseline, 3 months, then annually — not the monthly-then-quarterly schedule described; this characterization misrepresents the labeled protocol.
• Option E: Option E is incorrect because hepatotoxicity risk with ETI is not determined entirely by baseline ALT at initiation, and patients with normal baseline LFTs are not confirmed non-responders to hepatotoxicity; ongoing monitoring is required for all ETI-treated patients per label regardless of baseline values.

ANSWER: E

Rationale:

This case illustrates a clinically important transition pharmacology scenario. During lumacaftor-ivacaftor therapy, lumacaftor's potent CYP3A4 induction substantially accelerated tacrolimus metabolism, requiring a doubling of the tacrolimus dose (from 4 mg to 8 mg twice daily) to maintain therapeutic trough concentrations. The elevated dose was pharmacologically necessary to compensate for lumacaftor-driven CYP3A4-mediated tacrolimus clearance acceleration. When lumacaftor-ivacaftor is discontinued and the patient transitions to ETI — neither of whose corrector components (elexacaftor, tezacaftor) induce CYP3A4 — the CYP3A4 induction that required the higher tacrolimus dose will resolve over the days to weeks following lumacaftor discontinuation as the induced CYP3A4 enzyme concentration returns to baseline. As lumacaftor's induction wanes, tacrolimus will be metabolized progressively more slowly at the same dose, and trough concentrations will rise — potentially to supratherapeutic levels that risk tacrolimus nephrotoxicity. The tacrolimus dose must therefore be proactively reduced at or before the transition to ETI, with intensive trough monitoring during the transition period (ideally every 3 to 5 days initially) to guide stepwise dose reduction toward the pre-lumacaftor-ivacaftor dose requirement. Anticipating this transition pharmacology is essential for patient safety.

• Option A: Option A is incorrect because elexacaftor is not a CYP3A4 inducer; the claim that ETI induces CYP3A4 more potently than lumacaftor is pharmacologically incorrect, and tacrolimus dose requirements will fall, not rise further, after the switch.
• Option B: Option B is incorrect because lumacaftor-ivacaftor and ETI do not have equivalent CYP3A4 induction profiles; lumacaftor is a strong CYP3A4 inducer while tezacaftor and elexacaftor are not CYP3A4 inducers; continuing the same high tacrolimus dose after removing the CYP3A4 induction pressure will cause tacrolimus accumulation.
• Option C: Option C is incorrect because tezacaftor is not a CYP3A4 inhibitor; ETI does not raise tacrolimus concentrations through tezacaftor-mediated CYP3A4 inhibition, and tacrolimus dose reduction before the switch based on this fabricated mechanism is not pharmacologically justified.
• Option D: Option D is incorrect because tacrolimus is metabolized by both CYP3A4 and CYP3A5 in the liver and intestine; lumacaftor's CYP3A4 induction has substantially affected tacrolimus metabolism throughout the treatment period, as evidenced by the doubled tacrolimus dose requirement; the claim that CYP3A4 induction had no effect on tacrolimus contradicts the clinical observation in this case.

ANSWER: C

Rationale:

The resolution of chest tightness and absence of respiratory adverse effects on ETI is pharmacologically explained by the specificity of the respiratory adverse effect to lumacaftor-containing regimens. The respiratory adverse effect — chest tightness, worsening dyspnea, and acute FEV1 decline — is a recognized adverse event that occurs in a subset of lumacaftor-ivacaftor-treated patients, with the highest frequency and severity in those with FEV1% predicted below 40% at baseline, as this patient had (baseline 41%). The mechanism is incompletely characterized but is specific to lumacaftor's pharmacological properties; neither tezacaftor nor elexacaftor produces this adverse effect. The fact that this patient's chest tightness resolved promptly after stopping lumacaftor-ivacaftor and did not recur after initiating ETI confirms that the adverse effect was attributable to lumacaftor specifically, not to CFTR correction in general or to ivacaftor as the shared potentiator component. The simultaneous FEV1 improvement from 44% to 56% at 3 months on ETI — a substantially larger gain than the 3-percentage-point improvement over 14 months on lumacaftor-ivacaftor — further confirms that his modest prior response was partly limited by the lumacaftor-related respiratory adverse effect compromising his lung function, and that ETI provides superior F508del CFTR rescue through the dual-corrector synergy of elexacaftor and tezacaftor without this limitation.

• Option A: Option A is incorrect because the respiratory adverse effect of lumacaftor-ivacaftor is not caused by dose-dependent ivacaftor toxicity; ivacaftor is the shared potentiator in both regimens, and the adverse effect resolves when the corrector is changed from lumacaftor to tezacaftor/elexacaftor while ivacaftor is retained; the total ivacaftor dose difference between the two regimens is not the pharmacological explanation.
• Option B: Option B is incorrect because lumacaftor's respiratory adverse effect is not mechanistically attributed to MRP4 inhibition or intracellular cyclic AMP accumulation; this mechanism is pharmacologically fabricated.
• Option D: Option D is incorrect because the respiratory adverse effect of lumacaftor-ivacaftor is a pharmacological property of the drug, not an IgE-mediated hypersensitivity to tablet excipients; the temporal relationship — developing within the first week and affecting patients with more severe baseline disease at highest frequency — is consistent with a pharmacological adverse effect, not a formulation allergen response.
• Option E: Option E is incorrect because lumacaftor does not antagonize beta-2 adrenergic receptors; its mechanism is CFTR protein correction at the ER level, and it has no established pharmacodynamic interaction with beta-2 receptors or catecholamine signaling in airway smooth muscle.

ANSWER: B

Rationale:

The contrast between lumacaftor-ivacaftor and ETI with respect to warfarin dose requirements is pharmacologically straightforward and clinically significant. Lumacaftor is a broad cytochrome P450 enzyme inducer that upregulates both CYP3A4 and CYP2C9. CYP2C9 is the primary enzyme responsible for the metabolism of S-warfarin — the pharmacologically active enantiomer that accounts for the majority of warfarin's anticoagulant effect. CYP2C9 induction by lumacaftor accelerates S-warfarin hepatic metabolism, reducing S-warfarin plasma concentrations and decreasing its anticoagulant effect, which manifests clinically as falling INR values requiring progressive warfarin dose escalation to maintain therapeutic anticoagulation. This is the same mechanism by which lumacaftor-ivacaftor produces the tacrolimus-lowering interaction seen in this patient. By contrast, neither tezacaftor nor elexacaftor — the corrector components of ETI — induces CYP2C9. On ETI, warfarin metabolism proceeds at the patient's intrinsic CYP2C9 rate, determined by pharmacogenomic CYP2C9 genotype (slow, intermediate, or extensive metabolizer) and dietary vitamin K intake, without any additional lumacaftor-driven enzyme induction burden. The anticoagulation pharmacist's question therefore has a pharmacologically meaningful answer: had the patient remained on lumacaftor-ivacaftor, his warfarin dose would have needed to be substantially higher to achieve the same therapeutic INR that can be achieved at a lower standard dose on ETI.

• Option A: Option A is incorrect because CFTR modulators do not all produce equivalent CYP2C9 induction; lumacaftor is a CYP2C9 inducer while tezacaftor and elexacaftor are not, and this is a clinically established pharmacological distinction with real consequences for drugs metabolized by CYP2C9 such as warfarin.
• Option C: Option C is incorrect because lumacaftor is a CYP3A4 and CYP2C9 inducer — not a P-glycoprotein inhibitor producing increased warfarin bioavailability — and tezacaftor is not a CYP2C9 inhibitor; the interaction profiles described for both regimens in this option are reversed from reality.
• Option D: Option D is incorrect because warfarin is not absolutely contraindicated with lumacaftor-ivacaftor; the interaction is managed with progressive dose escalation and intensive INR monitoring, not by prohibiting warfarin entirely; warfarin anticoagulation is feasible on lumacaftor-ivacaftor with appropriate management, though more complex.
• Option E: Option E is incorrect because ivacaftor is not a clinically significant CYP2C9 inhibitor at therapeutic plasma concentrations; no warfarin-raising interaction from ivacaftor CYP2C9 inhibition is established in the pharmacological literature or prescribing labeling; and the proposed mechanism of a net-zero combined effect is pharmacologically unfounded.

ANSWER: D

Rationale:

The ETI prescribing label specifies that liver function tests should be measured before initiating ETI, at 3 months after initiation, and then annually in clinically stable patients, with a recommendation to monitor more frequently if transaminase elevations occur or if the patient has pre-existing hepatic disease. The labeled interrupt thresholds are absolute laboratory values referenced to the population ULN: ALT or AST exceeding five times the ULN without hepatotoxicity symptoms, or three times the ULN with symptoms. These thresholds are applied to the laboratory ULN — not to the patient's individual pre-treatment or ETI-period baseline ALT — so an ALT of 1.6 times the ULN at the current visit remains well below the labeled 5-times-ULN asymptomatic interrupt threshold and does not itself trigger any action. However, this patient's clinical complexity — a transplanted allograft liver, baseline ALT elevation from tacrolimus-related congestion, ongoing tacrolimus immunosuppression, and a history of CF-related liver disease that led to transplantation — provides strong clinical justification for more frequent LFT monitoring than the labeled annual minimum for stable patients. The label itself acknowledges this by recommending increased monitoring frequency for patients with pre-existing hepatic disease. The CF team retains its independent ETI monitoring obligations regardless of hepatology involvement; both teams should coordinate monitoring intervals and thresholds transparently. If ETI-related hepatotoxicity develops against the background of the patient's existing hepatic complexity, interpreting the significance of rising LFTs and making interruption decisions requires close collaboration between CF and hepatology specialists.

• Option A: Option A is incorrect because the labeled interrupt thresholds are referenced to the population ULN, not to the patient's individual ETI-period baseline; an ALT doubling from 1.6 to 3.2 times the ULN would still be below the labeled 5-times-ULN asymptomatic threshold, and no such "doubling of baseline" threshold is specified in the ETI label.
• Option B: Option B is incorrect because the label does specify guidance for patients with pre-existing hepatic disease — recommending more frequent monitoring — and clinical judgment requires recognizing this patient's complexity as warranting increased monitoring frequency beyond the minimum labeled annual schedule; applying the standard schedule uniformly without recognizing the clinical complexity is clinically inadequate.
• Option C: Option C is incorrect because ETI is not contraindicated in patients with ALT greater than 1.5 times the ULN at baseline; no such labeled exclusion threshold exists; this patient was successfully initiated on ETI 12 months ago and is tolerating it well, and restarting lumacaftor-ivacaftor in a post-transplant patient with known tacrolimus co-administration and a history of lumacaftor-related respiratory adverse effects would be clinically inappropriate.
• Option E: Option E is incorrect because the CF team retains independent ETI prescribing and monitoring obligations defined in the ETI prescribing label regardless of the concurrent involvement of the hepatology team; drug-specific monitoring requirements do not transfer to subspecialty consultants; both teams share responsibility for coordinated LFT surveillance in this complex patient.